MedTrace Logo

Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)

NCT01284218 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23514

Last updated 2013-11-08

No results posted yet for this study

Summary

To examine the differences in health care utilization and costs between MDD patients on adjunctive aripiprazole therapy and MDD patients on other augmentation therapies.

Conditions

  • Depressive Disorder, Major

Sponsors & Collaborators

  • i3 Innovus

    collaborator INDUSTRY

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

    lead INDUSTRY

Principal Investigators

  • Bristol Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-12-31
Completion
2011-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01284218 on ClinicalTrials.gov